1-Deoxynojirimycin To Mitigate Hepatic Ischemia- Reperfusion
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Mar 20, 2025
app pub date -
Sep 18, 2023
filing date -
Sep 18, 2023
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A method of mitigating Hepatic Ischemia-Reperfusion (Hep I/R) in a subject includes administering to a subject in need thereof a therapeutically effective amount of a 1-Deoxynojirimycin (1-DNJ) composition. The 1-DNJ composition can effectively treat and mitigate Hep I/R at dose ranging from about 50 mg/kg/day to about 100 mg/kg/day. 1-DNJ reduced the level of one or more inflammatory mediators (e.g. TNF-α, IL-6, IL-10), reduced the level of one or more oxidative stress-related biomarkers (e.g. CAT, SOD, GST, GSH, MDA, NO), reduced the level of one or more hepatic function biomarkers (e.g. ALT, AST, ALP, LDH) and increased the level of IL-10.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully